MedImmune Archives -

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s

AZ pulls back on Inovio immuno-oncology pact

https://pharmaphorum.com/news/az-pulls-back-on-inovio-immuno-oncology-pact/

AstraZeneca/ News/ News/ R&D

AstraZeneca to present the latest cardiovascular research

Piotr Wnuk AstraZeneca, cardiovascular, hyperkalaemia, MedImmune 0 Comment

AstraZeneca and MedImmune will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio for the treatment

AstraZeneca to present the latest cardiovascular research

https://pharmaphorum.com/news/astrazeneca-presents-latest-cardio-research/

AstraZeneca/ News/ News/ R&D/ Top pharmaceutical companies

AZ forges surprise R&D deal with virus gene therapy biotech

Piotr Wnuk AstraZeneca, gene therapy, genetics, MedImmune 0 Comment

MedImmune, the R&D arm of AstraZeneca has teamed up with California based 4DMT, a next-generation virus-based gene therapy

AZ forges surprise R&D deal with virus gene therapy biotech

https://pharmaphorum.com/top-pharmaceutical-companies/astrazeneca/az-steps-avv-field-medimmune-4dmt/

Partner content/ Press releases

MedImmune Expert Speaker Interview released in run up to Immuno-Oncology Conference

Lyudmyla Durneva cancer, immunooncology, MedImmune 0 Comment

SMi Group reports: Exclusive interview with Grace Macaulay – MedImmune released in the run up to the Immuno-Oncology

MedImmune Expert Speaker Interview released in run up to Immuno-Oncology Conference

https://pharmaphorum.com/partner-content/medimmune-expert-speaker-interview-released-in-run-up-to-immuno-oncology-conference/

News/ News/ R&D/ Top stories

AstraZeneca’s respiratory biologic fails again in COPD

Linda Banks AZ, COPD, Fasenra, MedImmune, respiratory biologic, respiratory disease 0 Comment

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

Oncology/ Views & Analysis/ Views and analysis

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 months

Andrew McConaghie AstraZeneca, Bahija Jallal, HBA, MedImmune 0 Comment

AstraZeneca’s Bahija Jallal was named the Healthcare Businesswomen’s Association (HBA) Women of the Year for 2017 – in what turned out to a watershed year for women’s rights.

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 months

https://pharmaphorum.com/views-analysis-oncology/bahija-jallal-pharmas-women-of-the-year-in-a-landmark-12-months/

Digital and Social Media/ News/ UK & Europe

MedImmune launches Digital Health Challenge in the UK

Andrew McConaghie digital health, MedImmune, start ups 0 Comment

Start ups and entrepreneurs in the UK who have developed or are looking to create a digital healthcare solution are being invited to submit entries to a new prize fund organised by Medimmune.

MedImmune launches Digital Health Challenge in the UK

https://pharmaphorum.com/news/38683/